Focus on The Path Forward for Orviglance
Ascelia Pharma (STO:ACE) today published its Half-Year Report for 2026 (January - June), which is now available on the company's website: Financial Reports - ASCELIA KEY EVENTS IN Q2 2026 Ascelia Pharma completed a directed share issue of SEK 20 million before transaction costs Bulletin from the Annual General Meeting in Ascelia Pharma AB on 4 May 2026 Orviglance data presented at the Annual Radiology Congress ESGAR 2026 Orviglance IP Portfolio...
Read more









